Aurion Biotech to Highlight Momentum Across Upcoming Eye Bank and Ophthalmology Meetings in June
Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision, today announced that the company will present at the Eye Bank Association of America (EBAA) 2026 Annual Meeting, taking place in Indianapolis, Indiana, from June 3-6 and at the American-European Congress of Ophthalmic Surgery (AECOS) 2026 European Symposium, June 11-14 in Madrid, Spain.
Aurion has been invited for the first time to participate in a panel discussion at EBAA, focused on Innovative Solutions in the field. Separately, Aurion will join a panel presentation at AECOS, where the conversation will center on the latest advances in corneal therapy.
Despite significant advances in keratoplasty, high unmet needs remain for corneal endothelial disease patients. Worldwide there are 500,0001 new cases annually, but fewer than 87,0002 patients receive treatment each year. Aurion’s regenerative cell therapy has the potential to transform care, expanding the gift of sight from one donor to help thousands of patients.
“We are grateful for the invitation to speak at this year’s EBAA Annual Meeting,” said Eris Jordan, OD, Chief Development Officer of Aurion Biotech. “The EBAA has long championed the belief that the gift of sight belongs to everyone. Aurion was founded on that same conviction. Together, we honor every donor by transforming a single donor cornea into the power to restore vision for over a thousand patients in need.”
